Showing results (321-330 of 355) with videos related to

Sort By:
Pageof 36
ACS Medicinal Chemistry Letters|June 6, 2014
Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing InteractionsJamison B Tuttle, Marie Anderson, Bruce M Bechle, et al.
Liver Cancer|October 9, 2025
Curative Treatment after Immunotherapy Leads to Excellent Outcomes in Patients with Hepatocellular CarcinomaGwang Hyeon Choi, Hyun-Seok Kim, Michael Luu, et al.
JHEP Reports : Innovation in Hepatology|June 30, 2025
The association between stage migration and overall survival after radiation-based therapies in patients with hepatocellular carcinomaSuraj Pai, Amit G Singal, Shengchen Hao, et al.
Hepatology (Baltimore, Md.)|April 22, 2025
AI-based phenotyping of hepatic fiber morphology to inform molecular alterations in metabolic dysfunction-associated steatotic liver diseaseNaoto Fujiwara, Yuki Matsushita, Mina Tempaku, et al.
Bioorganic & Medicinal Chemistry Letters|February 18, 1999
Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocketL A Reiter, J P Rizzi, J Pandit, et al.
The American Journal of Gastroenterology|July 17, 2024
The Liver Cirrhosis Network Cohort Study: Cirrhosis Definition, Study Population, and EndpointsElliot B Tapper, David Goldberg, Neehar D Parikh, et al.
Med (New York, N.Y.)|July 28, 2021
A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosisNaoto Fujiwara, Masahiro Kobayashi, Austin J Fobar, et al.
Hepatology (Baltimore, Md.)|November 15, 2021
Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver DiseasesSumeet K Asrani, Marwan S Ghabril, Alexander Kuo, et al.
Cancer|July 7, 2022
Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinomaNeehar D Parikh, Neil Mehta, Maarouf A Hoteit, et al.
Bioorganic & Medicinal Chemistry|March 28, 2007
Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective alphavbeta3 inhibitor: design, synthesis, and optimizationSrinivasan R Nagarajan, Hwang-Fun Lu, Alan F Gasiecki, et al.
Pageof 36